A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer

Pharmacokinetics and Metabolism of [14C] BMS-275183 in Patients With Advanced Cancer

The first purpose of this study is to determine how the body absorbs, metabolizes, and eliminates a single dose of BMS-275183 (labeled with radioactive carbon). Secondly, to measure the levels of BMS-275183 in your blood, study the safety of the drug, and to see what effects it has on your cancer.

Inclusion Criteria:

• Non-hematological malignancy that has progressed on standard therapy
• No more that 3 prior chemotherapies given for advanced cancer
• Adequate renal, hepatic and hematologic function

Exclusion Criteria:

• Uncontrolled or significant pulmonary or cardiovascular disease
• Active Brain metastases
• Inability to swallow capsules
• Serious uncontrolled medical disorder or active infection